As the combined expression of CD47 and SIRPα is potentially an independent prognostic factor for DLBCL, the levels of CD47 and SIRPα before CD47 blockade therapy need to be evaluated [12]. Here, SIRPA is linked to diffuse large B-cell lymphoma.